Objective: Trans-catheter aortic valve implantation (TAVI) technology is rapidly evolving, with 412 procedures having been performed at our institution. Herein, we report a complete, prospective analysis of complications occurring during transvascular and trans-apical implantations with two different prostheses. Methods: Between June 2007 and June 2010, 412 patients (258 female, mean age 80.3 AE 7.2 years, logistic EuroSCORE (European System for Cardiac Operative Risk Evaluation) 20.2% AE 13.0%) underwent TAVI through either a retrograde (n = 252 transfemoral, n = 28 transaxillary, and n = 5 transaortic) or antegrade (n = 127 trans-apical) approach at our institution. The trans-apical access was chosen only in cases where transvascular implantation was not possible. As many as 283 CoreValve and 129 Edwards Sapien prostheses were implanted. Results: Thirty-day survival was 90.9%. Vascular complications occurred in 42 patients (10.2%). In four patients, lethal aortic root (n = 3) or abdominal (n = 1) aortic rupture occurred. Pericardial effusion developed in 53 patients (12.8%), which resulted in cardiac tamponade in 12 patients (2.9%). Twenty-three patients (5.6%) with valve malplacement were treated interventionally. In five patients (1.2%), emergency institution of cardiopulmonary bypass was required during the procedure for temporary support; all patients survived. Seventeen patients underwent re-intervention on the catheter valve (4.1%). Conclusions: With growing experience, complications with TAVI may be avoided by proper patient selection and skillful management. Other complications, when they occur, require a specific treatment algorithm to avoid delay in decision making. A considerable number of complications after TAVI require surgical treatment. Therefore, the ideal environment for TAVI procedures is a hybrid operating room, where a multidisciplinary team of surgeons, cardiologists, and anesthesiologists is best fitted to meet the current needs associated with TAVI technology. A reduction in complications was seen after 300 cases. This finding attests to the complexity of the procedure in addition to the experience required to reduce the incidence of complications. #
Trans-catheter aortic valve implantation (TAVI) is a novel therapeutic option for high-risk patients with aortic stenosis. Since Cribier [1] performed the first-in-man trans-catheter implantation of an aortic valve substitute in 2002, the technique has been further developed and has entered daily routine in some centers. The target population for TAVI are elderly patients with severe co-morbidities and an increased risk for surgical aortic valve replacement (SAVR) [2, 3] . Technical feasibility has been proven by several groups [4] [5] [6] [7] , though the incidence and management of procedurerelated complications remain a field of current investigation. The trans-catheter treatment is associated with complications different from other catheter procedures and from SAVR. The present study systematically reviews the incidence and management of procedure-related cardiovascular complications after 412 cases from a group performing retrograde arterial and antegrade transapical TAVI by an interdisciplinary team in a hybrid suite. In addition, algorithms for the prevention and management of those complications are provided, which were obtained during the learning curve.
Methods
Between June 2007 and June 2010, we prospectively collected the data of 412 patients undergoing TAVI via either a trans-arterial or trans-apical approach at the German Heart Center, Munich. During this time, 283 CoreValve and 129 Edwards Sapien prostheses were implanted. The access-site approach and patient characteristics are summarized in Table 1 .
Patient selection, preoperative evaluation, and choice of access site
Symptomatic patients with severe aortic stenosis deemed either high risk or inoperable for SAVR were considered for trans-catheter valve implantation. Clinical judgment in conjunction with surgical risk score estimates (specifically, the logistic EuroSCORE (European System for Cardiac Operative Risk Evaluation) and Society of Thoracic Surgeons (STS) score) provided the basis for identification of high-risk patients. Informed consent was obtained from all patients. The local ethics committee approved the study (2234/08).
All patients underwent computed tomography of the thorax, abdomen, and pelvis with three-dimensional (3D) reconstructions of the arterial vasculature and aortic root. Coronary angiography was used to assess for coronary artery disease. Percutaneous revascularization, if required, was performed in a staged manner prior to TAVI (median time to TAVI: 55 days (2-141 days)). In all patients, the annulus diameter was measured by transthoracic and transesophageal echocardiography. The transfemoral access route is evaluated as initial default strategy for all patients. To accommodate the 18-F Medtronic CoreValve delivery system, the minimum cut-off vessel diameter is 6.5 mm. On the other hand, the 22-F and 24-F Edwards Sapien delivery system requires a minimum vessel diameter of 7 and 8 mm, respectively. If the transfemoral route was not eligible (vessel diameter too small, severe tortuosity, and previous peripheral bypasses or stents), we sequentially evaluated the subclavian, transapical, and ascending aorta for access.
Implantation techniques
Details of the device and technical aspects of the procedure have been previously published [4, 6, [8] [9] [10] . Briefly, all patients were operated in a surgical hybrid suite by an interdisciplinary team consisting of surgeons, cardiologists, and anesthesiologists. In the first 174 patients treated transfemorally, we opted to perform the procedures under general anesthesia to assure stable hemodynamics and avoid patient movement during valve implantation. More recently, we started to perform transfemoral implantations under light sedation (n = 65). As an added safety precaution, arterial and venous guide wires were placed into one groin at the beginning of the procedure in anticipation for the need of femoral-femoral bypass. Transfemoral valve implantation was performed either by percutaneous puncture and device closure (ProStar XL, Abbott Vascular, IL, USA; n = 167) or by surgical cut-down of the femoral artery (n = 85). Subclavian access was obtained by surgical cut-down (n = 28). Antegrade TAVI was performed through a left anterolateral minithoracotomy (n = 127). In five patients, retrograde implantation through the ascending aorta was performed through a partial upper ministernotomy. A transient pacemaker wire was placed either transvenously or epicardially during transarterial and trans-apical valve implantation, respectively.
Definition of end points
For the purposes of this study, we documented the following intraprocedural cardiovascular end points: [11] and includes new coronary obstruction documented by angiography or coronary obstruction that results in (a) new ischemic symptoms (e.g., chest pain or shortness of breath), (b) new ischemic signs (e.g., ventricular arrhythmias, new or worsening heart failure, new STsegment deviations -either elevation >1 mm or depression >1 mm in two or more contiguous leads, hemodynamic instability, or imaging evidence of new loss of viable myocardium or new wall motion abnormality), and (c) confirmatory biomarker evidence, consisting of two or more samples for creatinine kinase-MB (CK-MB) that are 6-8 h apart with a 20% increase in the second sample and a peak value exceeding 10Â the 99th percentile upper reference limit (URL) or a peak value exceeding 5Â the 99th percentile URL and with new pathological Q waves in at least two contiguous leads. Mechanical coronary artery obstruction may result from (i) impingement of the coronary ostia by the valve support structure in the setting of suboptimal valve positioning; or (ii) embolization from calcium, thrombus, air, or endocarditis; or (iii) displacement of native aortic valve leaflets toward the coronary ostia (during TAVI). (6) Re-intervention: The need for either trans-catheter (specifically, valve-in-valve) or SAVR for clinically significant valve malfunction (e.g., central or paravalvular aortic regurgitation).
Data collection and statistical analysis
Patients' baseline characteristics, intraprocedural data and postprocedural complications were prospectively recorded in a computerized database. Continuous variables are presented as means (AESD). Categorical variables are presented as frequencies and percentages. Differences between trans-arterial and trans-apical groups were analyzed by unpaired Student's t-tests (continuous variables), chi-square tests, or Fisher's exact tests (dichotomous or nominal variables), as appropriate. Kaplan-Meier survival estimates were performed for patients with and without complications and compared with the log rank test. Statistical significance was set at a 0.05 probability level. All statistical analyses were performed with Statistical Package for Social Sciences (SPSS) 16.0 German.
Results
Thirty-day, 6-month, and 1-year survival were 90.9%, 78.9%, and 77.4% without differences between access routes (see survival curve, Fig. 1 ). In-hospital mortality was 12.9%. Table 2 summarizes the intra-and periprocedural complica-tions that occurred in our patient population with respect to the access site for implantation. Patients without occurrence of procedural cardiovascular complications had a significantly better survival (30 days, 6 months, and 1 year: 96.5%, 84.7%, and 83.0% vs 79.5%, 67.4%, and 66.2% in patients with complications, p < 0.001, see Fig. 2 ).
Intraprocedural cardiac depression
Intraprocedural cardiac depression occurred in 75 cases. A total of 49 patients could be stabilized with catecholamine treatment alone. In 21 patients, successful cardiopulmonary resuscitation (CPR) was performed. In four of those patients, additional defibrillation was necessary. Immediate installation of cardiopulmonary bypass was required in five patients. All could be weaned successfully after hemodynamic stabilization.
Vascular complications
Vascular complications occurred in 42 patients (10.2%). Rupture of the ascending aorta occurred in three patients. In one of these cases, ascending aortic rupture occurred upon trans-apical delivery of an Edwards Sapien prosthesis and immediate conversion to median sternotomy ensued. In the other two cases, delayed ascending aortic rupture occurred following the implantation of a Medtronic CoreValve prosthesis 27 and 24 h after the initial procedure, respectively. Delayed lethal rupture of the descending aorta occurred in a patient with a previously stent-treated abdominal aneurysm 4 h after a Medtronic CoreValve implantation. A clinically unapparent descending aortic dissection was treated conservatively.
Complications from the femoral access site were observed in 33 patients (n = 2 Sapien, n = 31 CoreValve, 13.1% of 252 transfemorally treated patients). Three patients underwent implantation of a covered stent for vessel rupture. In 12 patients, surgical suture of the vessel leakage was performed, and five patients required surgical interposition of a vascular prosthesis. Twelve patients underwent surgical revision for hematoma, embolism, vessel occlusion, or false aneurysm. There were significantly less femoral access-site complications (5/85, 5.9%), if the femoral artery was dissected free as compared with the use of a vessel closure device (28/167, 16.8%, p = 0.015).
One patient experienced subclavian artery injury during a CoreValve implantation and the vessel was repaired by interposition of a vascular prosthesis. Another patient showed asymptomatic subclavian artery dissection after CoreValve implantation.
Two patients experienced radial artery dissection or rupture after insertion of the sheath for pigtail placement (n = 2 transfemoral CoreValve). Both underwent surgical fasciotomy of the arm.
Prosthesis malplacement
Prosthesis malplacement did not occur with the Edwards Sapien prosthesis, but in 23/283 patients (5.6%) treated with a CoreValve prosthesis. In 19 patients, a partially deployed Medtronic CoreValve prosthesis dislocated into the ascending aorta. All patients could be treated by retrieval of the partially deployed prosthesis through the introducer sheath and de novo placement after crimping the same prosthesis again onto the deployment catheter. In four patients, a completely deployed CoreValve prosthesis dislocated into a supra-annular position. In all of these patients, the prosthesis could be retracted with a 'goose-neck' catheter into the ascending or descending aorta, and a second prosthesis was implanted intraannularly.
Pericardial effusion
A total of 53 patients showed postprocedural pericardial effusion, of whom 12 developed pericardial tamponade.
In 42 patients, echocardiographic evidence of pericardial effusion was <1 cm. All underwent meticulous echocardiographic monitoring during the postoperative stay. Three of those developed cardiac tamponade 3 h, 2, and 3 days after the procedure and received uneventful pericardial puncture.
Eight of 11 patients with echocardiographic signs of pericardial effusion >1 cm exhibited immediate hemodynamic impairment and underwent subxiphoid puncture (n = 4) or sternotomy (n = 4), respectively, in the hybrid suite. In the patients who underwent sternotomy, perforation of the left-ventricular myocardium by the wire was found to be a source of bleeding. The other three patients were transferred to the intensive care unit without immediate intervention, one of them requiring sternotomy 2 h postoperatively for cardiac tamponade.
Coronary ischemia
In eight patients (1.9%), signs of coronary ischemia developed. In one patient, a dislocated valve occluded the right coronary ostium (transfemoral CoreValve), which was resolved successfully by retraction of the prosthesis. Another patient (trans-apical Sapien) developed lethal left anterior descending (LAD) artery thrombosis. In three patients, native aortic valve calcium obstructed the left main stem after implantation of a Medtronic CoreValve (n = 1) or an Edwards Sapien (n = 2) prosthesis, respectively. The patients were treated by surgical removal of the prosthesis and SAVR, coronary artery bypass grafting, and left main stenting. Two patients showed elevated cardiac markers postoperatively due to unknown reasons. One patient with postoperative ventricular fibrillation and emergent cardiac catheterization underwent stenting of an embolic RCA occlusion and recovered without residuals.
Re-intervention for valve malfunction
An intervention on the implanted catheter valve was required in 17 patients (4.1%).
Due to hemodynamically relevant central or paravalvular regurgitation, seven patients (1.7%) underwent a valve-in-avalve implantation (n = 3 transfemoral Medtronic CoreValve, n = 4 trans-apical Edwards Sapien) during the initial procedure. In six patients with a Medtronic CoreValve, clinically significant central or paravalvular regurgitation developed postoperatively and these patients were also treated with a valve-in-a-valve procedure 2 days to 3 months after the initial procedure. In three other patients with progressively increasing paravalvular leakage, a Medtronic CoreValve prosthesis was replaced by SAVR. One patient had clinically significant central regurgitation as a result of a trapped Sapien leaflet by native valve tissue and underwent surgical excision of the native aortic valve leaflet.
Learning curve
The frequency of any complication decreased from 38% in the first 300 patients to 17% in the last 112 patients ( p < 0.001) (Fig. 3) . More specifically, vascular complications decreased from 12% to 4.5% ( p = 0.019) and prosthesis malplacement decreased from 7% to 2% ( p = 0.040). There was no change in the incidence of cardiac depression, cardiac tamponade, re-intervention, or coronary ischemia.
Discussion
Trans-catheter aortic valve treatment is associated with complications different from other catheter procedures and different from complications following SAVR. During our learning curve, algorithms for the prevention and management of these complications were developed.
Vascular complications
Acute or delayed aortic root rupture is a rare but serious complication (<1% in our series) that may occur after balloon valvuloplasty or after valve implantation, especially in elderly women with fragile tissue where bulky calcifications may perforate the aortic root. Other groups describe Fig. 3 . Incidence of the reported complications (vascular complications, prosthesis malplacement, cardiac depression with resuscitation, pericardial tamponade, re-intervention on the catheter valve, and coronary ischemia) during the first 300 cases (black bars) and the last 112 cases (gray bars). A significant reduction in the incidence of complications was seen for vascular complications (from 12.3% to 4.5%, p = 0.019) and for prosthesis malplacement (from 7% to 1.8%, p = 0.040).
individual cases of aortic root rupture [12] , or ascending aortic dissection [12, 13] . The prognosis is usually poor, even if emergent open surgical repair is performed [12, 13] . Naturally, preoperative meticulous annulus measurements by computed tomography (CT) scan and echocardiography are mandatory to avoid oversizing of the balloon or prosthesis. In our own series, this serious complication occurred exclusively in the early period of our implantation experience, without having a clear explanation for this finding.
Peripheral vessel rupture, dissection, or bleeding requiring interventional or surgical treatment occurred in 13.1% of the 252 transfemorally treated patients in our patient population, and is described in 7-20% of the cases by other groups [4, [14] [15] [16] [17] [18] [19] with population sizes of only 10-50 patients. These early reports do not suggest a considerable difference between the two valve types. Our data demonstrate a significant reduction of vascular access-site complications with a surgical cut-down compared with a vessel closure device. We therefore refined our percutaneous technique and perform the puncture of the access site only after crossing a pigtail catheter from the contralateral femoral artery, which serves to hit the artery in its central portion. Before removal of the femoral sheath, a Terumo wire is again crossed from the contralateral artery for potential balloon insertion, if the closure device fails. In very obese patients or in patients with severe calcifications, we opt for a surgical cut-down.
Furthermore, we caution against choosing the transfemoral access in patients with previous iliac-or aortic-stent implantation, as one patient in our series experienced descending aortic rupture at the site of a previously implanted abdominal aortic stent.
Prosthesis malplacement
The management of prosthesis dislocation requires highly skilled catheter expertise and emergent surgery in some cases. The incidence of Medtronic CoreValve dislocation was 5.6% in our series (23/283) . Literature data are rare, with only one other group reporting an incidence of 3% [20] . Dislocation of the Edwards Sapien prosthesis has been reported to occur in 4-11% in five series [4, 6, 12, 18, 21] , whereas our group did not experience this complication. Reasons for dislocation of a partially deployed CoreValve prosthesis are instability in the aortic root during deployment due to severe regurgitation after balloon valvuloplasty, unfavorable angulation, and thoracic or abdominal aortic kinking, which may lead to uncontrollable movements at the implantation site following manipulations from the groin. We now exclude patients with more than mild thoracic or abdominal kinking from transfemoral TAVI. To improve stabilization of the valve during deployment, higher-rate ventricular pacing may be performed, especially in patients with aortic insufficiency. Alternatively, the subclavian artery access may be chosen. A completely deployed Medtronic CoreValve prosthesis may also dislocate accidentally after successful deployment by retraction of the delivery system if the anchors are not fully released from the deployment catheter, or if the tip of the deployment catheter gets caught at the proximal end of the prosthesis. This is prevented by reassurance that both anchors are released, which may sometimes require the exact exposure of the anchors in different imaging levels. Furthermore, pulling on the intraventricular Amplatz super stiff wire centers the conical tip of the delivery system, which can then be removed without touching the proximal valve stent.
Dislocation of a partially or completely deployed Medtronic CoreValve or Edwards Sapien prosthesis into the ascending aorta can be managed interventionally in most cases, as described above. Both valves are at risk for dislocation if either the annulus is too large, or secondary intraprocedural dilation of the implanted prosthesis is performed, or rapid pacing is terminated too early. Thus, meticulous annulus measurements by echocardiography and CT are paramount, and rapid pacing should be stopped only after complete deflation of the balloon during secondary dilation of the already deployed valve. Embolization of the Edwards Sapien prosthesis into the ventricle has been described to occur under circulatory support with the heart-lung machine with retrograde perfusion from the femoral artery. This complication may only be treated surgically.
Cardiac depression
Cardiac depression with a considerable decrease of blood pressure requiring resuscitation occurred in 6.3% (26/412) of the cases in our series. Other groups describe individual cases [17] , or incidences of emergent installation of extracorporeal bypass in 12-25% [12, 21] , and ventricular fibrillation in 4-11% [4, 18] . Some minor cardiac depression occurs usually in most patients after rapid pacing for balloon valvuloplasty or after valve deployment, especially in patients with predisposing conditions, such as impaired left-ventricular function, severe myocardial hypertrophy, or severe pulmonary hypertension. In patients with an extremely reduced valve-opening area, the delivery system in the annulus may even cause subtotal obstruction. In these cases, relatively fast deployment with relief of the obstruction is paramount. To prevent circulatory depression, it is recommended to start with rapid pacing only if the systolic arterial pressure is above 100 mmHg.
In the majority of the patients, circulatory depression is successfully treated with administration of catecholamines alone. Resuscitation and the institution of extracorporeal circulatory support are necessary only in a minority of the cases. To facilitate emergent installation of extracorporeal bypass, arterial and venous guide wires may be placed in the groin prior to the procedure. As all of the five patients in the present series could be weaned successfully after emergent extracorporeal circulatory support, a standby heart-lung machine should be considered a standard of care for TAVI procedures. Depending on other causes of low cardiac output, therapy could include coronary angiography and intervention, pacing, or pericardial puncture.
Pericardial effusion
In the present series, periprocedural pericardial effusions occurred in 12.9% (53/412) of patients. In approximately a quarter of these patients, clinical signs of hemodynamically relevant tamponade developed (12/412, 2.9%). Data from the literature reveal an incidence of pericardial tamponade in 2-8% [6, 12, 15, 18, 20, 22] . The origins of a hemorrhagic pericardial effusion are multifactorial and they may occur promptly during valve implantation, or may be delayed. The source of bleeding may be the right ventricle, following perforation of the transient pacemaker wire. Perforation of the left ventricle may occur with a fixed core wire, or with the Judkins or multipurpose catheters after valve passage. Some preventive strategies may help to avoid these injuries: In addition to applying the usual precautions established in interventional cardiology, some measures are specific for TAVI procedures. Meticulous care should be taken to bend the tip of the Amplatz super stiff wire manually in an appropriate fashion prior to insertion into the left ventricle. A correct position of the guide wire within the left ventricle is crucial. The tip should be non-attached to the ventricular wall, and the curve of the wire should line the septum and apex within the cavity of the left ventricle.
As for the management of pericardial effusions, we have established the following algorithm for our institution: As a standard of care, all patients should undergo echocardiographic control for the identification of pericardial effusion at the end of the implantation procedure. Small effusions <10 mm without hemodynamic impairment are monitored echocardiographically at close intervals. Patients with rapidly increasing effusions and with effusions causing hemodynamic impairment (central venous pressure (CVP) increase, blood pressure decrease, and tachycardia) undergo pericardial puncture and insertion of a drain. If no improvement of the symptoms is achieved, emergent sternotomy is performed.
Myocardial ischemia
Coronary ischemia and cardiac marker elevation are seen in 0-27% [4, 12, [14] [15] [16] 20, 21, 23] of patients after TAVI and occurred in 1.9% (8/412) of our patients from various reasons. Coronary ischemia due to a dislocated prosthesis is consequently treated by interventional retraction of the prosthesis. Left-main-stem obstruction by native valve calcium is rare [4, 12] and requires surgical removal of the prosthesis, or may be treated with coronary artery bypass grafting or left main stem stenting in some cases [12] . Close inspection of the echocardiographic and CT images for unusual native leaflet excrescence might allow anticipation of this complication [12] . Thrombembolic coronary occlusion is treated interventionally. In all patients with clinically significant postoperative cardiac marker elevation, cardiac catheterization should be performed immediately.
Re-intervention on the catheter valve
Re-intervention may be required in cases of valve malfunction or high-degree paravalvular leakage. Only sparse data are available on the need for re-interventions after TAVI. In our series, surgical removal of a catheter valve and subsequent SAVR was required in cases of hemodynamically relevant paravalvular leakage. In the present series, intra-operative central or severe paravalvular leakage could be resolved by implantation of a second trans-catheter valve during the same procedure. This approach has been described also by Grube et al. [20] in 3/136 patients. An event not yet described in the literature occurred in six other patients of our series: delayed development of central or paravalvular regurgitation in a Medtronic CoreValve prosthesis up to 3 months after the initial procedure. All patients could be treated again interventionally by implantation of a second catheter valve. Close echocardiographic follow-up investigations are mandatory for the identification of this complication.
Learning curve
Our observation of a learning curve was based exclusively on the reduction of cardiac procedural complications. Based on the objectives of our study, other clinical end points such as mortality, stroke, and complete heart block were not analyzed in the context of a learning curve. A search for a learning curve was conducted at an interval of every 50 TAVI cases. Having said that, we noticed a reduction in complications only after 300 cases. This finding attests to the complexity of the procedure in addition to the experience required to reduce the incidence of complications. However, the fact that more than one operator was involved during establishment of the TAVI program at our center might have contributed to a longer learning curve.
Conclusion
TAVI is an exciting new technology that offers an alternative treatment for high or prohibitive surgical-risk patients with aortic stenosis. Although TAVI avoids the use of extracorporeal circulation and sternotomy, it is nonetheless associated with inherent complications. Some of the procedural complications may be attributed to a specific learning curve and thus be avoided in the future: aortic root rupture by precise measurement of the root diameters and by excluding patients with bulky calcifications, ventricular rupture by even more careful manipulation of the wires, prosthesis malplacement by avoiding patients with unfavorable aortic anatomy, peripheral vessel injury by seeking alternative access sites, considerable intraprocedural cardiac depression by meticulously maintaining sufficient intraprocedural perfusion pressure and respect time for myocardial recovery, just to mention a few. Other complications require a specific treatment algorithm to avoid time delay for decision making when they occur. In addition, a highly specialized and motivated team with excellent cooperational skills should perform all the implantations to circulate the experience gained.
Dr T. Walther (Bad Nauheim, Germany): Very important data. An important point was made by the discussant. I think your approach is very nice as a team, and we all should not stay away or run out when there is a vascular complication. If we are surgeons and want to be part of this game, trans-catheter valves, we have to deal with the problems. If the team has a femoral complication, we don't call the vascular surgeons. We know how to stitch a femoral vessel. You made that very clear. I just want to emphasize that. I think it is very important that we are part of the whole game, to stay in the game for the next 10 years and longer.
